| Biomarker ID | 121 |
| PMID | 16434583 |
| Year | 2006 |
| Biomarker | BSAP |
| Biomarker Basis | Concentration Based (U/L) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in Bone Metastatis PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:- Inhibitor of DNA binding (ID) signaling pathway,C-Myb transcription factor network |
| Experiment | Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | 165 patients with various cancers (lung, bresast and prostate) were compared. Total 42 patients had Prostate Cancer, out of which 25 did not have Bone metastatis and 17 had Bone Metatsatis. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | ELISA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | PAX5 |